Skip to main content

Advanced Search

Projected result for your current search:: 0

Search Operators:

You can use operators in your search query to narrow down your results even more. Click on the search operator to see an explanation of how it works.
Finds documents with exactly this word group, in exactly this word order and spelling (e.g. "employer branding").
Finds documents with both search terms (e.g. sales AND bonus).
Finds documents with one or the other search term (e.g. porsche OR volkswagen).
Finds documents with all search terms. Blank space is understood as AND (e.g. man robot production).
Finds documents with no appearance of the word behind NOT (e.g. ford NOT "harrison ford").
Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g. COUNT(gear)>8).
Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g. NEAR(recruit, professionals, 20)).
Finds documents with the search term in word versions or composites. The asterisk * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g. lightweight*, *lightweight, *lightweight*).
Finds documents with the search term in different spellings. "?" allows only one character (e.g. organi?ation).
Special characters are understood as AND (e.g. Miller Bros. & Sons).
 Log in
Top
Current Cardiology Reports

Will Factor XI Inhibitors Replace Current Anticoagulants for Stroke Prevention in Atrial Fibrillation?

  • 23-07-2024
  • Atrial Fibrillation
  • Invasive Electrophysiology and Pacing (EK Heist and S Nedios, Section Editors)
Published in:
Authors
Siddharth M. Patel
Christian T. Ruff
Published in
Current Cardiology Reports | Issue 9/2024

Abstract

Purpose of Review

This review provides an overview of the factor XI (FXI) inhibitor hypothesis for the development of novel anticoagulants which may be safer to those currently used in clinical practice and describes preliminary clinical data from phase 2 dose-ranging studies of patients with atrial fibrillation.

Recent Findings

Recent data from phase 2 dose ranging studies demonstrate substantial reductions in bleeding with FXI pathway inhibition compared with currently approved anticoagulants. However, larger studies are necessary to demonstrate efficacy of FXI inhibition for stroke prevention in atrial fibrillation.

Summary

FXI pathway inhibition holds great promise for revolutionizing the landscape of anticoagulation for atrial fibrillation, primarily by reducing bleeding risk; however, further data are necessary to demonstrate efficacy.
Title
Will Factor XI Inhibitors Replace Current Anticoagulants for Stroke Prevention in Atrial Fibrillation?
Authors
Siddharth M. Patel
Christian T. Ruff
Publication date
23-07-2024
Publisher
Springer US
Published in
Current Cardiology Reports / Issue 9/2024
Print ISSN: 1523-3782
Electronic ISSN: 1534-3170
DOI
https://doi.org/10.1007/s11886-024-02100-y
This content is only visible if you are logged in and have the appropriate permissions.

Other articles of this Issue 9/2024

Hypertrophic Cardiomyopathy: From Medical Treatment to Advanced Heart Failure Therapies

Curbing the Obesity Epidemic: Should GLP-1 Receptor Agonists Be the Standard of Care for Obesity?

  • Obesity
  • Public Health Policy (SS Virani and D Mahtta, Section Editors)

Molecular Regulation of Cardiac Conduction System Development

  • Pacemaker
  • Regenerative Medicine (SM Wu, Section Editor)

Obesity Paradox in Transcatheter Aortic Valve Replacement

  • Obesity
  • Valvular Heart Disease (TL Kiefer, Section Editor)

Electrophysiological Cardiovascular Magnetic Resonance (EP-CMR)-Guided Interventional Procedures: Challenges and Opportunities

  • Atrial Flutter
  • Invasive Electrophysiology and Pacing (EK Heist and S Nedios, Section Editors)

How to Optimize Goal-Directed Medical Therapy (GDMT) in Patients with Heart Failure

  • Open Access
  • Heart Failure
  • Heart Failure (HJ Eisen, Section Editor)

Next-generation MRI contrast agents: preparing the field (Link opens in a new window)

New MRI contrast agents are reshaping diagnostic imaging, promising lower gadolinium exposure amid evolving practice guidelines. How can you optimise contrast selection, dosing, and patient care in this rapidly advancing field?

This content is intended for healthcare professionals outside of the UK.

Independent Medical Education Grant:
  • Bayer HealthCare Pharmaceuticals Inc.
Learn more Link opens in a new window
Image Credits
Abstract graphic of layered, concentric circular shapes in bright green, pink, blue, and purple on a dark blue background. The rings and segments form a complex radial pattern without text/© Springer Health+ IME